Analytical Methods: A Statistical Perspective on the ICH Q2A and Q2B Guidelines for Validation of Analytical Methods - - BioPharm International


Analytical Methods: A Statistical Perspective on the ICH Q2A and Q2B Guidelines for Validation of Analytical Methods

BioPharm International
Volume 19, Issue 12

Table 7. A typical precision analysis
Once the data are collected, one has the proverbial chicken-or-egg decision; in this case, accuracy or precision. Since accuracy and precision go hand-in-hand, the decision of which to assess first involves personal preference. Here, for the sake of simplicity, accuracy will be assessed first, then precision. Accuracy is calculated by combining all data across analysts and days for each level of analyte. Depending on the method being validated, acceptance criteria should be established. For the following example, one can use a percent recovery of 95–105%. A typical accuracy analysis is shown in Table 6.

Table 8. A typical linearity analysis
Without a precision analysis, one cannot confirm accuracy claims. The intermediate precision includes analyst and day, while the repeatability includes the variability within analyst per day. Each source of variability is assessed and then combined to yield the intermediate precision and repeatability. A typical precision analysis is contained in Table 7.

Once one has shown acceptable precision and accuracy, one can assess if the bias is constant by performing a linearity analysis. Using the same data from the accuracy and precision analysis, an ordinary least squares (OLS) estimate can be calculated. Two coefficients are estimated using OLS: the slope and intercept. A lack-of-fit test confirms that the linear model is appropriate for the data set. Combining all the data similar to the accuracy analysis yields the linearity analysis contained in Table 8. A graphical representation of the data is shown in Figure 2. The model illustrates a statistically significant slope with a lack-of-fit test showing that the linear model is sufficient (for lack-of-fit test, a p-value greater than 0.05 is indicative that the model is sufficient). The intercept is not statistically significant (p > 0.05), indicating that the assay would run through the origin.

Since the accuracy, precision, and linearity all meet the requirements, one can state that the range of the assay is 50–150%.


Figure 2
Using a well-designed experiment and statistically relevant methods, method validation can be accomplished in accordance with the ICH guidelines. Precision analysis is the most critical component because it allows the claims of accuracy and linearity to be made.

Steven Walfish is president of Statistical Outsourcing Services and BioPharm Editorial Board Member, 403 King Farm Boulevard, Suite 201, Rockville, MD 20850, 301.325.3129, fax: 301.330.2143,


1. Krause SO. Analytical method validation for biopharmaceuticals: a practical guide. Guide to Validation. Supp to BioPharm Int. 2005 Mar; 26–34.

2. Kanarek AD. Method validation guidelines. Guide to Bioanalytical Advances. Supp to BioPharm Int. 2005 Sep; 28–33.

3. US Food and Drug Administration. Guidance for industry: Q2B validation of analytical procedures: methodology. Rockville, MD: Nov 1996.

4. US FDA. Guideline for industry: text on validation of analytical procedures: ICH Q2A. Rockville, MD: Mar 1995.

5. Rodbard D. Statistical estimation of the minimal detectable concentration (sensitivity) for radioligand assays. Analytic Biochem. 1978;90:1–12.

6. Hauck WW, Capen RC, Callahan JD, De Muth JE, Hsu H, Lansky D, et al. Assessing parallelism prior to determining relative potency. PDA J Pharma Sci Technol. 2005;59(2):127–37.

7. Daniel C, Wood FS. Fitting equations to data. 2nd ed. New York: Wiley & Sons; 1980.

8. Dixon WJ, Massey FJ. Introduction to statistical analysis. New York: McGraw-Hill; 1969.

9. Box GEP, Hunter WG, Hunter JS. Statistics for experimenters. New York: Wiley & Sons; 1978.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here